View Peter Geschek's Articles BY TICKER:
Pfizer Vs. Eli Lilly, Novartis In Breast Cancer Race
- Palbociclib’s overall survival rate is not statistically significant but Pfizer is still the leader.
- Competitors Novartis and Eli Lilly are working hard to catch up.
- Sell Pfizer? Some thoughts.
Sovaldi's Patent War
- Now that Sovaldi is a success, a number of companies want a piece of it.
- Gilead will spare no expense in this fight.
- Expensive court fights are part of the reason for high drug prices.
Biogen's Winning Strategy
- Biogen is rapidly expanding into other diseases beyond multiple sclerosis.
- It has a chance to gain three FDA approvals this year.
- The value of the pipeline should be added to Biogen’s valuation.
Sovaldi's Terrific Launch
- Sovaldi, Gilead’s oral Hepatitis C drug, by all accounts is having a fantastic launch.
- The usual bickering about its high cost is louder than usual because of the large number of patients.
- It’s time to consider the cost of not using this wonder drug.
Johnson & Johnson's Success In Cardiac Ablation
- Johnson & Johnson’s subsidiary Biosense Webster has beat St. Jude Medical to the U.S. market in getting its improved SmartTouch catheter FDA approved.
- The catheter is contact-sensing: it shows the physician the amount and direction of the force being applied during procedure.
- Competing TactiCath from St. Jude Medical is expected to follow in 7-9 months.
- Studies are underway to prove that catheter ablation is as effective as medication in the treatment of atrial fibrillation.
Pfizer's Coming Superdrug
- Palbociclib, an experimental breast cancer drug, is considered the crown jewel in Pfizer’s pipeline.
- In February, Pfizer announced that results from the Paloma-1 study demonstrated a statistically significant improvement in progression-free survival of breast cancer patients.
- Pfizer's palbociclib and Novartis' experimental LEE011 are locked in a race to become the first CDK4/6 inhibitor to reach the market.
- Palbo has a unique mechanism of action, and could become a mainstay in the treatment of hormone-receptor positive breast cancer.
- GLP-1 Race In Diabetes: Eli Lilly Vs. Competitors
- The Vaccine Prevnar 13 And Its Competitor: Pfizer Vs. Merck
- Attack On Lung Cancer: Eli Lilly Vs. Rivals
- Innovation In Huntington's Disease: Auspex Vs. Rivals
- Frantic Pace In Cancer Immunotherapy: Merck Vs. Bristol-Myers
- The Hep C Race Is Heating Up: AbbVie Vs. Gilead
- The Dream Of The Insulin Pill: Oramed Vs. Rivals
- The Leukemia Race: Gilead Vs. Johnson & Johnson, Roche
- The CoreValve Battle: Medtronic Vs. Edwards Lifesciences
- Liver Drug Race: Intercept Pharma Vs. Rivals
- High Stakes Intrigue In Hep C: Bristol-Myers Vs. Gilead
- The Psoriatic Arthritis Race: Celgene Vs. Johnson & Johnson
- Capricor: Can A Scarred Heart Be Repaired?
- Amgen Vs. Merck, Lilly In Osteoporosis Competition
- Is Puma Biotech's High Stock Price Justified?
- Bristol-Myers Squibb Vs. Roche In The Brain Cancer Race
- Acceleron, Celgene Vs. Amgen In The Anemia Drug Race
- Acadia: The Best Hope For Parkinson's Psychosis Sufferers
- Biogen's Biosimilars Vs. Amgen, Johnson & Johnson
- Merck Vs. Bristol In PD-1 Cancer Drug Race
- Hep C Price War? Abbvie Vs. Gilead
- Oncomed, Celgene Vs Rivals In Cancer Stem Cells Race
- HeartWare Vs. Thoratec In The Heart Pump Race
- Johnson & Johnson Vs. Pfizer, Bristol In The Race Of Anticoagulants
- Celgene Vs. Amgen In Multiple Myeloma Battle
- Portola's Antidote Could Benefit Pfizer, Bristol-Myers, J&J